An observational study in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Philipps University Marburg. Completed at 22 sites in Germany. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-04-12.
Sponsored by Philipps University Marburg · Observational
The purpose of this study is to determine the prevalence and severity of extrapulmonary disorders and to quantify the impact of extrapulmonary organ manifestations on morbidity and mortality of COPD patients.
Furthermore the investigators evaluate the relationship between systemic inflammation and organ involvement.
Chronic diseases and comorbidities have an increasing impact on individual life and health care use, as exemplified in chronic obstructive pulmonary disease (COPD). Currently, independent, comprehensive databases allowing for an integrated view are lacking. The study will for the first time establish a large, comprehensive longitudinal database covering a broad panel of comorbidities an markers of systemic alterations. These data will be of unique value in revealing specific phenotypes of COPD via patterns and risk profiles of comorbidities, enabling a more precise diagnosis and targeting of therapy, and an efficient allocation of resources.
4,252 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 707 are open to participants now.
This study's enrollment of 2,741 is above the median of 183 across 1,099 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Browse Pulmonary Disease, Chronic Obstructive studies →Philipps University Marburg is the lead sponsor of 116 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Since the original recruitment strategy was not as successful as expected,the mode of recruitment was extended to other physicians, patients' groups and organisations and advertising to local media. The recruitment is supported by professional measures of communication organized by the coordinating centre Marburg.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Change from baseline in BODE-Score at 18 months
The BODE-Score comprises BMI, airway obstruction, dyspnea and exercise capacity and is a good predictor for death in COPD patients. Progression is defined as a change in BODE-score by \>=1 point over the observation period.
Time frame: at initial visite, after 18, 36, 54, 72, 90 and 108 months
COPD related mortality
The rate of mortality was elevated after 6, 18, 36, 54, 72, 90 and 108 months
Time frame: after 18 months
COPD related hospitalization
The rate of hospitalizations was elevated in every visit.
Time frame: after 18, 36, 54, 72, 90 and 108 months
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →